Neurology
Spastic Cerebral Palsy
6
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Spastic Cerebral Palsy is an early-stage landscape with 6 programs across 4 companies. The most active players are Merz Pharmaceuticals GmbH, Ipsen, Revance Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
8
clinical trials
Completed5 · 63%
Terminated1 · 13%
Unknown status1 · 13%
Not yet recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
The Effect of Botulinum Toxin Injection at Hip Adductor Muscles in Patients With Spastic Cerebral Palsy, Pilot Study
Completed·—·N/A·NCT03680196·20 enrolled
Bimanual Training Versus Unilateral Task Specific Training in Children With Spastic Hemiplegic Cerebral Palsy
Completed·—·Preclinical·NCT07437274·46 enrolled
Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial
Terminated·—·Phase 2·NCT02434549·16 enrolled
Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy
Unknown status·TThe Second Affiliated Hospital of Fujian Medical University·Phase 1·NCT03107975·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)